donq52
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2022 (NCT05425446)
Timeline
Indications
Studied for
Mechanism of action
- GlutenINHIBITOR
Gluten inhibitor
HLA-DQA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07239336 | Phase 2 | Dec 15, 2025 | Chugai |
| NCT05425446 | Phase 1 | Sep 19, 2022 | Chugai |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chugai | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1